MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Regulation FD DisclosureItem 7.01
On July26, 2018, the Company issued a press release announcing its receipt of a letter from the Nasdaq staff notifying the Company that its stock will be delisted unless the Company requests a hearing before a Nasdaq Listing Qualifications Panel by July27, 2018. The full text of the press release is furnished as Exhibit 99.1 on this Current Report on Form 8-K and is incorporated herein by reference.
| Item 7.01 | Financial Statements and Exhibits |
(c) Exhibits
MIMEDX GROUP, INC. ExhibitEX-99.1 2 d553594dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 MIMEDX ANNOUNCES RECEIPT OF NASDAQ LETTER Company Will Request Hearing with Nasdaq Hearings Panel Marietta,…To view the full exhibit click here
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.